Yong Huang
About Yong Huang
Yong Huang serves as the Senior Director of Bioinformatics and Head of Biopharma for Predicine in the San Francisco Bay Area, where he has worked since 2019. He holds a Ph.D. in Bioinformatics and Computational Biology and has extensive experience in genomic data analysis and molecular diagnostics.
Work at Predicine
Yong Huang has been serving as the Senior Director of Bioinformatics and Head of Biopharma (China) at Predicine since 2019. In this role, he oversees bioinformatics initiatives and biopharmaceutical projects within the organization. His responsibilities include managing bioinformatics analysts and ensuring the effective application of data analysis techniques to support clinical trials and diagnostics.
Previous Experience at WuXi AppTec
Prior to his current position, Yong Huang worked at WuXi AppTec China as a Principal Scientist from 2014 to 2016. In this capacity, he contributed to various projects within the biopharmaceutical sector, utilizing his expertise in bioinformatics and data analysis to enhance research outcomes.
Education and Expertise
Yong Huang holds a Doctor of Philosophy (Ph.D.) in Bioinformatics and Computational Biology from Iowa State University, where he studied from 2004 to 2010. Additionally, he earned a Master's degree in Statistics from the same institution during the same period. His academic background provides a strong foundation for his expertise in data mining, statistical interpretation, and visualization of next-generation sequencing (NGS) results.
Research Experience at Howard Hughes Medical Institute
Yong Huang served as a Postdoctoral Research Associate at the Howard Hughes Medical Institute from 2010 to 2014. During this time, he conducted research at UCSF, focusing on bioinformatics applications in clinical settings. His work involved the analysis of whole genome sequencing (WGS), whole exome sequencing (WES), and RNA sequencing data for disease gene discovery and tumor genomics.
Specialization in Molecular Diagnostics
Yong Huang possesses a deep understanding of diagnostic aspects in clinical trials and specializes in the application of molecular diagnostic biomarkers. His expertise includes working with biomarkers such as BRCA, homologous recombination repair (HRR), copy number variation (CNV), and tumor mutational burden (TMB). This specialization supports his role in advancing precision medicine initiatives.